LegalCaseDocs.com
shopping cart  
  |     
Search
 

 
New Visitors


 VeriSign Secure Site

 Get Adobe Reader

CCS v PFIZER INC and PARKE-DAVIS Click to find out why . . .



Keywords & Phrases
CaseNo: CVPIAPD153655, CourtName: MISC 4, Plaintiff: CCS, State: CA California, UniqueCaseRef: LCD>CVPIAPD153655, Parke-davis, Neurontin, Representative Action, Unfair Competition Law, Complaint, Violation, Physicians, Off-label, Medical Liaisons, Drug, Doctors, California, Payments, Articles, Consultants, Fda, Neurontin Prescriptions, Investigators, Publication Strategy, Medical Education, Los Angeles, California Seniors, Bipolar Disorder, Clinical Trials, Hagens Berman Llp, High Doses, Regulations, Conference , ContentID: 120254705

Case Documents
1   CLASS ACTION COMPLAINT
[ see first page and extracted highlights below  ] ItemID: 131797
49 pages
PDF
Total Documents: 1 document , 49 pages
Price: $ 19.95


IVESLCD01 KGI0001
 
 

 Forgot your password?


1 . CLASS ACTION COMPLAINT

EXTRACTED KEY WORDS
NEURONTIN
REPRESENTATIVE ACTION
UNFAIR COMPETITION LAW
COMPLAINT
VIOLATION
PHYSICIANS
OFF-LABEL
MEDICAL LIAISONS
PLAINTIFF
DEFENDANTS
DRUG
DOCTORS
CALIFORNIA
PAYMENTS
ARTICLES
CONSULTANTS
FDA
NEURONTIN PRESCRIPTIONS
INVESTIGATORS
PUBLICATION STRATEGY
MEDICAL EDUCATION
LOS ANGELES
CALIFORNIA SENIORS
BIPOLAR DISORDER
CLINICAL TRIALS
HAGENS BERMAN LLP
HIGH DOSES
REGULATIONS
CONFERENCE


 1     Amanda L. Horn (State Bar No. 213891)
       HAGENS
                     BERMAN
                                  LLP

 2     700 South Flower Street, Suite 2940
       Los Angeles, CA  90017-4101
 3     Telephone:  (213) 330-7150
       Facsimile:  (213) 330-7152
 4      -and-
       Steve W. Berman
 5     HAGENS BERMAN LLP
       1301 Fifth Avenue, Suite 2900
 6     Seattle, WA  98101
       Telephone: (206) 623-7292
 7     Facsimile: (206) 623-0594

 8     Attorneys for Plaintiffs

 9     [Additional Counsel Listed on Signature Page]

10
                                SUPERIOR COURT OF THE STATE OF CALIFORNIA
11
                                     FOR THE COUNTY OF LOS ANGELES
12
       CONGRESS OF CALIFORNIA SENIORS                         )      Case No.
13     ("CCS"), CALIFORNIA PUBLIC INTEREST  )
       RESEARCH GROUP; USACTION, individually )                      REPRESENTATIVE ACTION
14     and on behalf of itself and the general public,        )      COMPLAINT FOR VIOLATION OF
                                                              )      THE UNFAIR COMPETITION LAW
15      Plaintiffs,
                                                              )      AND THE FALSE ADVERTISING LAW
                                                              )
16      v.                                                    )
                                                              )
17     PFIZER, INC. and PARKE-DAVIS, a division  )
       of Warner-Lambert Company,                             )
18                                                            )      JURY TRIAL DEMANDED
        Defendants.
                                                              )
19                                                            )

20
                Plaintiffs, Congress of California Seniors ("CCS"), California Public Interest
21
SNIPPETS:
  • Los Angeles, CA 90017-4101
  • HAGENS BERMAN LLP
  • Plaintiffs, Congress of California Seniors, California Public Interest Research
  • Group and USAction by counsel and for their Representative Action
  • REPRESENTATIVE ACTION COMPLAINT FOR VIOLATION OF THE UNFAIR COMPETITION LAW
  • and sells the drug Neurontin.
  • Prior to its acquisition of Warner-Lambert, Neurontin was marketed
  • and sold by Parke-Davis,
  • There are strict federal regulations about what form that promotion can take.
  • The rules are meant to ensure that drug companies give doctors trustworthy information,
  • 12 received FDA approval to market and sell Neurontin for the treatment of epilepsy.
  • 17 potential in the "off-label" promotion of Neurontin for other diseases and at higher
  • using cash payments as a reward and incentive.
  • 25 training who are available at physicians' requests to provide balanced scientific
  • The medical liaisons were
  • 17 was that since Neurontin is safe at very high doses and produced no significant side
  • 14 from a Philadelphia company called Medical Education Systems.
  • In fact, three of the articles MES proposed, related
  • tens of thousands of bipolar disorder patients are now treated with Neurontin.
  • 10 Defendants as a result of their unlawful, unfair, or deceptive practices.
  • Complete diversity of citizenship between Plaintiff and Defendants does not
  • assume the expense and time necessary to conduct clinical trials necessary to prove that
  • Faced with the fact that its "publication strategy" required
  • 22 payments to both groups of physicians through "consultants'" meetings, speakers' bureaus,
  • the "consultants" were directly asked if they would write more Neurontin prescriptions
  • Neurontin scripts after the conference.
  • patients qualified for the study, the STEPS protocol called for over 1,200 "investigators" to
  •    |